EXACT Sciences Corporation (EXAS)

NASDAQ
Currency in USD
53.29
-0.23(-0.43%)
Closed·
After Hours
52.52-0.77(-1.44%)
·
EXAS Scorecard
Full Analysis
3 analysts have revised their earnings upwards for the upcoming period
EXAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
52.4554.52
52 wk Range
39.9772.83
Key Statistics
Edit
Prev. Close
53.52
Open
54.3
Day's Range
52.45-54.52
52 wk Range
39.97-72.83
Volume
2.33M
Average Vol. (3m)
2.8M
1-Year Change
27.79%
Book Value / Share
12.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EXAS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
68.86
Upside
+29.21%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

EXACT Sciences Corporation News & Analysis

Show more

EXACT Sciences Corporation Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXACT Sciences Corporation Earnings Call Summary for Q1/2025

  • Revenue grew 11% YoY to $707M, beating estimates; EPS missed at -$0.54 vs -$0.33 forecast
  • Stock surged 8.88% in aftermarket despite earnings miss; analysts remain bullish with $52-$85 price targets
  • Full-year revenue guidance raised to $3.070-$3.120B; adjusted EBITDA guidance increased to $425-$455M
  • CEO highlighted Cologuard's market leadership; new products like Cologuard Plus expected to drive future growth
  • Management confident in upcoming blood-based test performance; may accelerate payer coverage for new products
Last Updated: 05/01/2025, 06:14 PM
Read Full Transcript

Compare EXAS to Peers and Sector

Metrics to compare
EXAS
Peers
Sector
Relationship
P/E Ratio
−9.9x−4.8x−0.5x
PEG Ratio
0.03−0.010.00
Price / Book
4.2x3.2x2.6x
Price / LTM Sales
3.6x7.5x3.1x
Upside (Analyst Target)
28.4%487.5%51.1%
Fair Value Upside
Unlock10.2%8.9%Unlock

Analyst Ratings

22 Buy
4 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 68.86
(+29.21% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-0.54 / -0.33
Revenue / Forecast
707.00M / 688.78M
EPS Revisions
Last 90 days

EXAS Income Statement

People Also Watch

59.83
HIMS
+7.83%
101.49
BSX
+1.75%
53.90
ON
+5.64%
307.66
UNH
-1.87%
201.11
DHR
+0.22%

FAQ

What Is the EXACT Sciences (EXAS) Stock Price Today?

The EXACT Sciences stock price today is 53.29

What Stock Exchange Does EXACT Sciences Trade On?

EXACT Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for EXACT Sciences?

The stock symbol for EXACT Sciences is "EXAS."

What Is the EXACT Sciences Market Cap?

As of today, EXACT Sciences market cap is 10.03B.

What Is EXACT Sciences's Earnings Per Share (TTM)?

The EXACT Sciences EPS (TTM) is -5.50.

When Is the Next EXACT Sciences Earnings Date?

EXACT Sciences will release its next earnings report on Aug 05, 2025.

From a Technical Analysis Perspective, Is EXAS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has EXACT Sciences Stock Split?

EXACT Sciences has split 0 times.

How Many Employees Does EXACT Sciences Have?

EXACT Sciences has 6950 employees.

What is the current trading status of EXACT Sciences (EXAS)?

As of Jun 17, 2025, EXACT Sciences (EXAS) is trading at a price of 53.29, with a previous close of 53.52. The stock has fluctuated within a day range of 52.45 to 54.52, while its 52-week range spans from 39.97 to 72.83.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.